Atlas

Premium option selling portfolio

Continue reading the Atlas

Sign in or subscribe to read the full post and get every Atlas trade in your inbox.

Showing older Atlas headlines. Recent posts from the last 10 days are available to subscribers.
Cover Image for Unity's Disunity: Betting on a $28.50 Floor

Unity's Disunity: Betting on a $28.50 Floor

Unity Software trades like a pendulum in a hurricane. Today's $0.87 put premium at the $28.50 strike captures that volatility beautifully — 50% implied volatility on a name that's spent more time disa

Cover Image for CARS: Parking Our Cash Where the Analysts See Upside

CARS: Parking Our Cash Where the Analysts See Upside

While the automotive classified space gets little love from momentum traders, Cars.com presents an intriguing contrarian setup. We're selling the $10 put expiring in June 2026 for $0.30, essentially g

Cover Image for SAIA: Trucking Along at 50x Earnings (Someone's Got to Do It)

SAIA: Trucking Along at 50x Earnings (Someone's Got to Do It)

Selling puts on a trucking company trading at 50x earnings? In this market, that's practically value investing. SAIA sits 16% above its 50-day moving average and 36% above its 200-day, sporting a beta

Cover Image for Testing the Waters: RVTY's FDA Win Fuels Our Put Strategy

Testing the Waters: RVTY's FDA Win Fuels Our Put Strategy

Revvity's recent FDA clearance for its testosterone assay isn't just another regulatory checkbox—it's a glimpse into how this diagnostics player keeps expanding its testing portfolio. With the stock s

Cover Image for PATH of Least Resistance: UiPath's Automation Revolution at a Discount

PATH of Least Resistance: UiPath's Automation Revolution at a Discount

UiPath trades like yesterday's AI darling while building tomorrow's automation backbone. At $11.16, PATH sits 14% below its 200-day moving average despite sporting a healthy 17.5% profit margin and re

Cover Image for Gene Therapy Gets a Haircut: CRSP's Premium Pays While Science Waits

Gene Therapy Gets a Haircut: CRSP's Premium Pays While Science Waits

CRISPR Therapeutics trades like a biotech startup despite being a clinical-stage gene editing pioneer with actual approved therapies. At $51.59, CRSP sits near its 50-day moving average but well below

Cover Image for Big Blue's Big Premium: IBM's Quantum Leap or Classic Value Trap?

Big Blue's Big Premium: IBM's Quantum Leap or Classic Value Trap?

IBM is offering a rare gift: 49.5% implied volatility on a stock that barely moves. At $253.84, Big Blue sits comfortably above our $235 strike with 31 days to expiration, collecting $6.35 in premium

Cover Image for GDS: Data Centers and Dollar Signs

GDS: Data Centers and Dollar Signs

While everyone's chasing AI darlings at nosebleed valuations, GDS Holdings sits quietly in the corner — a Chinese data center operator trading at $40.41 with analysts pointing to $57. We're selling th

Cover Image for CPAY's Cross-Border Hustle: Betting on the B2B Payment Revolution

CPAY's Cross-Border Hustle: Betting on the B2B Payment Revolution

Corporate payments are having a moment, and Corpay is cashing in. The $11.8 billion fintech sits at the intersection of two massive trends: the digitization of B2B payments and the cross-border money

Cover Image for Lazard's Lazy River: Banking on M&A Recovery with a 34-Day Put

Lazard's Lazy River: Banking on M&A Recovery with a 34-Day Put

Investment banking boutiques have been swimming upstream for two years, but Lazard's latest moves suggest the current might be shifting. The $43 put on LAZ delivers 3.0% in 34 days — that's 32% annual

Atlas Portfolio results shown on this page are produced in a simulation environment using EOD market data and contract pricing. They are not records of trades placed in a brokerage account or executed with real capital, and individual results would vary based on fills, commissions, slippage, and account size. Tiblio is a software platform for finding and executing options trade ideas. We are not a registered investment advisor or broker-dealer. Nothing on this page is financial advice. Options trading involves substantial risk of loss. Past or simulated performance does not guarantee future results.